Serologic correlates of immunity in a tetravalent reassortant rotavirus vaccine trial

Journal of Infectious Diseases

Volumn 176, Issue 3, 1997, Pages 570-577

  Ward, Richard L ^a   Knowlton, Douglas R ^a   Zito, Edward T ^c   Davidson, Bruce L ^b   Rappaport, Ruth ^c   Mack, Michael E ^c  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b ALLEGHENY UNIVERSITY HOSPITALS   (United States)

^c Allegheny University Hospital ^*

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; NEUTRALIZING ANTIBODY; ROTAVIRUS SEROTYPE 1 VACCINE; ROTAVIRUS TETRAVALENT VACCINE; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PREDICTION; PRIORITY JOURNAL; ROTAVIRUS; SEROCONVERSION; SERODIAGNOSIS; VACCINATION; VIRUS IMMUNITY;

EID: 0030853004     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/514076     Document Type: Article

References (26)

1. Kapikian AZ, Chanock RM. Rotaviruses. In: Fields BN, Knipe DM, Howley PM. Fields virology. 3rd ed. New York: Lippincott-Raven Publishers, 1996:1657-708.
2. Institute of Medicine. Prospects for immunizing against rotavirus. In: New vaccine development, establishing priorities. Diseases of importance in developing countries. Vol 2. Washington, DC: National Academy Press, 1986:308-18.
3. Clark HF, Borian FE, Bell LM, Modesto K, Gouvea V, Plotkin SA. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype rotavirus season. J Infect Dis 1988;158: 570-87.
4. Vesikari T, Isolauri E, D'Hondt E, Delem A, Andre FE, Zissis G. Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet 1984;1:977-81.
5. Flores J, Perez-Schael I, Gonzalez M, et al. Protection against severe rotavirus diarrhoea by rhesus rotavirus vaccine in Venezuelan infants. Lancet 1987;1:882-4.
6. Bernstein DI, Smith VE, Sander DS, Pax KA, Schiff GM, Ward RL. Evaluation of WC3 rotavirus vaccine and correlates of protection in healthy infants. J Infect Dis 1990;162:1055-62.
7. Christy C, Madore HP, Pichichero ME, et al. Field trial of rhesus rotavirus vaccine in infants. Pediatr Infect Dis J 1988;7:645-50.
8. DeMol P, Zissis G, Butzler JP, Mutwewingabo A, Andre FE. Failure of live, attenuated oral rotavirus vaccine. Lancet 1986;2:108.
9. Hanlon P, Hanlon L, Marsh V, et al. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants. Lancet 1987;1:1342-5.
10. Santosham M, Letson GW, Wolff M, et al. A field study of the safety and efficacy of two candidate rotavirus vaccines in a Native American population. J Infect Dis 1991;163:483-7.
11. Chiba S, Yokoyama T, Nakata S, et al. Protective effect of naturally acquired homotypic and heterotypic rotavirus antibodies. Lancet 1986; 2:417-21.
12. Hoshino Y, Saif LJ, Sereno MM, Chanock RM, Kapikian AZ. Infection immunity of piglets to either VP3 or VP7 outer capsid protein confers resistance to challenge with a virulent rotavirus bearing the corresponding antigen. J Virol 1988;62:744-8.
13. Midthun K, Greenberg HB, Hoshino Y, Kapikian AZ, Wyatt RG, Chanock RM. Reassortant rotaviruses as potential live rotavirus vaccine candidates. J Virol 1985;53:949-54.
14. Midthun K, Hoshino Y, Kapikian AZ, Chanock RM. Single gene substitution rotavirus reassortants containing the major neutralization protein (VP7) of human rotavirus serotype 4. J Clin Microbiol 1986;24: 822-6.
15. Bernstein DI, Glass RI, Rodgers G, Davidson BL, Sack DA, US Rotavirus Vaccine Efficacy Group. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. JAMA 1995;273: 1191-6.
16. Rennels MB, Glass RI, Dennehy PH, et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - report of the National Multicenter Trial. Pediatrics 1996;97:7-13.
17. Ward RL, Bernstein DI, US Rotavirus Vaccine Efficacy Group. Lack of correlation between serum rotavirus antibody titers and protection following vaccination with reassortant RRV vaccines. Vaccine 1995; 13:1226-32.
18. Ward RL, Clemens JD, Sack DA, et al. Culture adaptation and characterization of group A rotaviruses causing diarrheal illnesses in Bangladesh from 1985 to 1986. J Clin Microbiol 1991;29:1915-23.
19. Ward RL, Bernstein DI, Shukla R, et al. Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus. J Infect Dis 1989;159:79-88.
20. Knowlton DR, Spector DM, Ward RL. Development of an improved method for measuring neutralizing antibody to rotavirus. J Virol Methods 1991;33:127-34.
21. Ward RL, Kapikian AZ, Goldberg KM, Knowlton DR, Watson MW, Rappaport R. Serum rotavirus neutralizing-antibody titers compared by plaque reduction and enzyme-linked immunosorbent assay-based neutralization assays. J Clin Microbiol 1996;34:983-5.
22. Estes MK, Cohen J. Rotavirus gene structure and function. Microbiol Rev 1989;53:410-49.
23. Dennehy PH, Rodgers GC Jr, Ward RL, et al. A comparative evaluation of reactogenicity and immunogenicity of two dosages of oral tetravalent rhesus rotavirus vaccine. Pediatr Infect Dis J 1996;15:1012-8.
24. Wright PF, King J, Araki K, et al. Simultaneous administration of two human-rhesus rotavirus reassortant strains of VP7 serotype 1 and 2 specificity to infants and young children. J Infect Dis 1991;164: 271-6.
25. Franco MA, Greenberg HB. Role of B cells and cytotoxic T lymphocytes in clearance of and immunity to rotavirus infection in mice. J Virol 1995;69:7800-6.
26. + cells in resolution of rotavirus infection and protection against reinfection in mice. Virology 1995;214:387-97.